For a wore better use of sereic temor warkers;Du bon usage clinique des marqueurs tumoraux sériques

Tunisie Medicale

Volumn 76, Issue 2, 1998, Pages 1020-1026

  Hammouda, Boussen ^a   El May, Michèle ^a   Jerbi, Ghazi ^a   Rahal, Khaled ^a   Benna, Farouk ^a   Mtimet, Sadok ^a   Ben Ayed, Farhat ^a  

^a SALAH AZAIEZ INSTITUTE   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADULT; BLOOD; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASM; PREGNANCY; PROGNOSIS; REVIEW;

ADULT; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PREGNANCY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 2442499638     PISSN: 00414131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Bidart JM, Bellet D. Les marqueurs biologiques de concer.La lettre du cancerologue 1993,vol II 84-88.
2. Hayes DF. What are tumor markers, and when should they be used ?. In American Society of Clinical Oncology Educational book 30th annual meeting.Dallas 1994. 138-149.
3. Bergstrand CG, Czar B. Demonstration of new protein fraction in serum from human foetus Scandinav J Clin Lab Invest 1956;8:174-80
4. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinoma by immunologic tolerance and absorption technique. J Exp Med 1965;121:439-460.
5. Egawa S, Soh S, Ohori M, Uchida T et al.The ratio of free to total prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan Cancer 1997,79:90-8
6. Longo DL Tumor markers.Semin in Oncology 1987,17:85-9.
7. Villers A. L'antigène spécifique prostatique. Revue du praticien-Médecine générale 1993;7:28-30.
8. Dover A, Daliford I. Les marqueurs biologiques sériques des cancers.Précisions sur leur nouveau rôle dans la stratégie de décision.Spectra biologie,No 93/6,61-75.Décembre 1993.
9. Basuyau JP, Brunelle P. Marqueurs tumoraux et fadeurs pronostiques biologiques dons les cancers du sein. Spectra biologie 1993:6;45-51.
10. Grem J. The prognostic importance of tumor markers in odenocarcinoma of the gastrointestinal trad.Current opin in oncology 1997,9 380-7.
11. Knapp RC, Jacobs I, Schwartz PE. Clinical perspectives in using CA 125. Contemporary OB/GYN february 1996:1-7
12. Roulston JE. Limitations of tumour markers in screening Br J Surg 1990,77.901-2
13. Van Den Bosch RP, Van Eicjk CHJ, Muder PGH et al. Serum CA 19-9 in the management of pancreatic cancer. Hepatogastroenterology 1996,43:710-3.
14. . Pirolo F, Pacini B, Borsotti M et al. The role of Ca 15-3 and MCA monoclonal antibody in the detection of primary and returrent breast cancer Anticancer Res 1991,11 729-732
15. Perdrisot R, Bigorgne JC. Guilloteau D, Jallet P. Monoclonal immunoradiometric assay of calcitonin improves investigation of familial medullary thyroid carcinoma.Clin Chem 1990;36.381-3.
16. Heyward WL, Bender TR, Kilkenny S, Kline KT, Lanier AP, Mc Mahon BJ, Paproki TR, Silimperi DR. Early detection of primary hepatocellular carcinoma by screening for alpha-foetoprotein in high-risk families Lancet 1983,1161-2
17. . Primary liver cancer study group of Japan. clinicopathologic features and results of surgical treatment. Ann Surg 1990,211 277-287.
18. Etude retrospective clinique et thérapeutique de 13 cas d'hépatoblastome de l'enfant traités de 1987 à 1994. Abdelmoula S Thése de doctoral en médecine. Faculté de médecine de Tunis. 1996.
19. . Colomer R, Ruibol A, Genolla J et al. Circulating CA 15-3 antigens levels in non-mammary malignancies. BR J Cancer 1989;59:283-6.
20. . Takahashi T, Kato T, Kodaira S, Koyamo Y et al. Prognostic factors of colorectol cancer Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy.Am J Clin Oncol 1996,19:408-415
21. Slenta K, Senagore A, Hibbert J, Mazier WP, Talbott TM. Can preoperative and postoperative CEA predict survival after colon cancer resection. Am Surg 1994;60:528-531.
22. . Frasci G, Conforti S, Zullo F et al. A risk model for ovarian carcinoma using CA 125 Time to normalization renders second look laparotomy redundant.Cancer 1995;77:1122-30.
23. . American society of clinical oncology : Clinical guìdelines for the use of tumor markers in breast and colo-rectal cancer.JCO 1996;14:2843-2877.
24. . Sauer H. et al Significance of tumor markers during the follow-up of women without symptoms after treatment of primary breast cancer. Anticancer Res 1997,17.3059-3061.
25. . Ruddon RW,Norton SE. Use of biological markers in the diagnosis of cancers of unknown origin. Seminars in onc 1993;20;251-260.
26. . Greco FA, Hainsworth JD. Tumors of unknown origin Cancer J Clin 1992,42:90-115.
27. . Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.JNCl 1996;88 1456-66.
28. Brown RW, Campagna LB, Dunn JK, Cagle PT. Immunohistochemical identification of tumor markers in metastotic adenocarcinomo.Am J Clin Pathol 1997,107.12-9.
29. Screston RA, Penn LZ, Stanners CP. Carcinoembryonic antigen, a human tumor marker cooperates with Myc and Bcl-2 in cellular transformation.J Cell Biol 1997,137:939-952.
30. Bonbardieri E, Massaron S, Martinetti A, Seregni E. Cost-effectiveness of tumor markers detection in cancer patients Int J Biol Markers 1997,12:47-8